

europaean journal of gynaecological oncology

an International Journal

Editors-in-Chief

A. Onnis **P. Bószé**
Montréal (Canada) Budapest (Hungary)

Associate Editor

M. Marchetti
Montréal (Canada)

Assistant Editor

J. Wilson
San Diego - CA (USA)

Editorial Board

Allen H.H., London, Ontario (Canada)	Geisler H.E., Indianapolis, IN (USA)	Monsonogo J., Paris (France)
Anteby S.O., Jerusalem (Israel)	Gerbaulet A., Villejuif (France)	Pálfalvi L., Budapest, (Hungary)
Audet-Lapointe P., Montreal (Canada)	Gorins A., Paris (France)	Pinotti A., São Paulo (Brazil)
Ayhan A., Ankara (Turkey)	Heintz A.P.M., Utrecht (The Netherlands)	Piura B., Beer Sheva (Israel)
Balat O., Graziantep (Turkey)	Ioannidou-Mouzaka L., Athens (Greece)	Piver S.M., Buffalo, NY (USA)
Barber H.K., New York, NY (USA)	Jordan J.A., Birmingham, England (UK)	Rakar S., Ljubljana (Slovenia)
Basta A., Krakow (Poland)	Karseladze A.I., Moscow (Russia)	Raju K.S., London, England (UK)
Bender H.C., Dusseldorf (Germany)	Klastersky J., Bruxelles (Belgium)	Shepherd J.H., London, England (UK)
Benedetti Panici P.L., Rome (Italy)	Kubista E., Vienna (Austria)	Stelmachów J., Warsaw (Poland)
Charkviani T., Tbilisi (Georgia)	Kudelka A.P., Houston, TX (USA)	Tjalma W., Antwerpen (Belgium)
De Oliveira C.F., Coimbra (Portugal)	Maggino T., Padua (Italy)	Ungár L., Budapest (Hungary)
Dexeus S. Jr., Barcelona (Spain)	Markowska J., Poznan (Poland)	Vermorken J.B., Edegem (Belgium)
Di Paola G.R., Buenos Aires (Argentina)	Marth C., Innsbruck (Austria)	Vîrtej P., Bucharest (Romania)
Di Re F., Milan (Italy)	Massuger Leon F.A.G., Nijmegen (The Netherlands)	Wang P.-H., Taipei (Taiwan)
Di Saia P., Orange, CA (USA)	Menczer J., Savyon (Israel)	Winter R., Graz (Austria)
Friedrich M., Hamburg (Germany)		Yokoyama Y., Hirosaki (Japan)
Fuller A.F. Jr., Boston, MA (USA)		

Publishing Organization (M. Morsani):

I.R.O.G. CANADA, Inc. - 4900 Côte St-Luc - Apt # 212 - Montréal, Qué. H3W 2H3 (Canada)
Tel. +514-4893242 - Fax +514-4854513 - E-mail: canlux@mgroun-online.com - www.irog.net

Editorial Office (M. Critelli):

Galleria Storione, 2/A - 35123 Padua (Italy) - Tel. (39) 049 8756900 - Fax (39) 049 8752018

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY (ISSN 0392-2936) publishes original peer reviewed works in the fields of female genital cancers and related subjects and also proceedings of gynecologic oncology society meetings all over the world. The Journal is covered by **CURRENT CONTENTS, SCISEARCH, RESEARCH ALERT, INDEX MEDICUS, MEDLINE, EMBASE/Excerpta Medica, CURRENT ADVANCES IN CANCER RESEARCH, BIOSIS.**

European Journal of Gynaecological Oncology

www.irog.net

General Information

The EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY (ISSN 0392-2936) publishes original peer reviewed work, preferably brief reports, in the fields of female genital cancers and related subjects – prevention, early detection, epidemiology, pathology, diagnosis, management – and also proceedings of Gynaecologic Oncology Society meetings all over the world.

The Journal is covered by CURRENT CONTENTS, SCISEARCH, RESEARCH ALERT, INDEX MEDICUS, MEDLINE, EMBASE/Excerpta Medica, CURRENT ADVANCES IN CANCER RESEARCH, BIOSIS.

AIMS AND SCOPE

The EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY is dedicated to publishing editorial articles in the “Distinguished Expert Series” and original research papers, case reports, letters to the Editor, book reviews and newsletters.

The Journal was founded in 1980 – the second gynaecologic oncology hyperspecialization journal in the world. Its aim is the diffusion of scientific, clinical and practical progress and knowledge in female neoplastic diseases in an interdisciplinary approach among gynaecologists, oncologists, radiotherapists, surgeons, chemotherapists, pathologists, epidemiologists and so on.

ANNOUNCEMENTS regarding meetings, postgraduate courses and symposia will be accepted six months before publication and will be published free of charge.

BOOK SAMPLES for review should be sent to the Editorial offices in Montréal or in Padova.

COPYRIGHT: the Journal has been registered with the Copyright Clearance Center, Inc. Reproductions are not allowed without the written consent of the Publisher. All photocopy fees should be paid to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA stating the ISSN number, the volume and the first and last page numbers of each article copied.

ADVERTISING INFORMATION: advertising orders and inquiries may be sent to: I.R.O.G. CANADA Inc., Publisher, 4900 Côte St. Luc, Apt. 212, Montréal (Quebec) Canada H3W 2H5, Tél. 514.4893242-4893640, Fax 514.4854513, E-mail: canlux@mgroup-online.com - www.irog.net

RESPONSIBILITY: although every effort is made by the editorial staff and the printer to eliminate misleading or inaccurate information, the publisher accepts no responsibility for the consequences of faulty or incorrect information. The authors recognize that the editor and publisher have no responsibility and are indemnified against any liability or claim that may result from the publication of misleading or incorrect data.

SUBSCRIPTION INFORMATION

The Journal is published bimonthly (January, March, May, July, September and November); one volume per year. Subscriptions start from January and are automatically renewed if not cancelled by the end of September.

Subscriptions include six issues per year plus supplements, monographs and all official communications of Meetings, Courses, Symposia and all scientific activities of Gynaecologic Oncology Societies all over the world.

Subscriptions are entered with prepayment only. The annual subscription is \$390 US for Institutions, \$200 US for Individuals. For airmail add \$30, for receipt add \$10 US. Single copy prepaid cost \$95 US.

Send subscription requests with cheque or credit card payment (Amex - Visa - Diner's - Master Card) to I.R.O.G. CANADA Inc., 4900 Côte St. Luc, Apt. 212, Montréal, Québec H3W 2H3 Canada. **Only US Funds are accepted.** No bank transfers.

Claims for missing issues can be honoured up to six months. **Changes of address:** allow six weeks for all changes to become effective. All communications should include both old and new addresses (with postal codes) – better if accompanied by a mailing label from a recent issue – and should be sent to the printer: La Garangola, Via E. Dalla Costa 6, 35129 Padova (Italy) or by Fax +39.049.7806580. Claims should be made within six months of publication date.

Duplicate copies will not be sent to replace those undelivered through failure to notify of change of address.

Single copies and back issue and volume information is available from the printer, La Garangola, Padova, Tel. +39.049.8075557, Fax +39.049.7806580. Certain back issues may only be available as photocopies of the originals.

All other business correspondence including orders for offprints and advertising space and **any communication and requests should be addressed to** I.R.O.G. CANADA Inc., 4900 Côte St. Luc, Apt. 212, MONTRÉAL, QUÉBEC H3W 2H3 (Canada), tel. (514) 4893242, fax (514) 4854513.

IN ALL LEGAL MATTERS THE COURT OF MONTREAL IS COMPETENT.

European Journal of Gynaecological Oncology

www.irog.net

Instructions to Authors

SUBMISSION OF MANUSCRIPTS

Papers should be submitted to A. ONNIS Editor-in-Chief of the EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 4900 Côte St. Luc, Apt. 212 MONTREAL, QUÉBEC H3W 2H3 (Canada) - Tel. +514-4893242 - Fax +514-4854513, or Galleria Storione 2/A - 35123 PADOVA (Italy) - Fax +39-049-8752018.

Editorial articles for publication in the "Distinguished Expert Series" should be submitted to P. Bószé, Editor-in-Chief of this section, Department of Gynecology, Saint Stephan Hospital, 1096 Budapest, Nagyvárad tér 1, Telephone (36-1) 275 2172, Fax (36-1) 275 2172, E-mail: bosze@axelero.hu

When a manuscript is submitted, an acknowledgement card is sent to the corresponding author within two or three weeks.

Submitted papers are reviewed by the Editor-in-Chief and his Peer Referees. Authors may be required to modify the manuscript according to the reviewers' suggestions.

Manuscripts accepted for publication will be copyedited by the editorial staff for typographical and grammatical mistakes and to guarantee clarity and conciseness.

Publication time will be the shortest possible based on scientific and publishing needs. Manuscripts submitted for publication cannot be returned.

Published papers will become property of the Journal and copyrighted under I.R.O.G. CANADA Inc.

After six months no grievances will be accepted regarding published articles.

All statements are the responsibility of the authors. Product dosages, indications and methods referred to in the papers reflect the author's experience. No responsibility is assumed by the Editor-in-Chief or the Publisher for any damage from use of any products, operation methods or instructions contained in the published materials.

Trade names, trademarks, etc. are protected by the law and regulations. The Editor-in-Chief and the Publisher cannot accept any legal responsibility for any errors or omissions that may be made in press, particularly for information about drug dosage and application thereof contained in the Journal. Consult the prescribing information before administering any drug.

MANUSCRIPT REQUIREMENTS

The Journal follows the "Uniform requirements for manuscripts submitted to biomedical journals" published in the *New England Journal of Medicine* 1991, 324, 424-8 and in the *British Medical Journal* 1991, 302.

Three *manuscripts* typed and double spaced should be submitted by mail (not by email) **with an electronic disk, formatted in Word for Macintosh or Windows, version 6.0.** Manuscripts without an electronic disk will not be accepted. **A cover letter signed by all authors must state that all authors who have participated in the work take responsibility for the manuscript which has never been published or submitted for publication elsewhere.** Without a cover letter the publication will not be possible. Name, address and phone/fax numbers of the *Corresponding Author*, responsible for revision and approval of the proofs, should be indicated. **Full-length articles should not exceed 8 printed pages including tables and references.**

After the *title page* (full title and names of authors, institutions, eventual acknowledgement for financial support, running title of no more than 60 characters or spaces), original works should be arranged in the conventional order: **Summary** (*purpose of investigation, methods, results, conclusion - about 150 words*), **Key words**, **Content** (a 20-word summary), **Introduction**, **Materials and Methods**, **Results**, **Discussion**, **Conclusion**, **Acknowledgement** (if any), **References**, **Tables**, **Legends**.

Authors should supply a complete address for reprint requests.

In the text only standard abbreviations can be used and must be avoided in the title. The full term for which an abbreviation stands should precede its first use in the summary and text unless it is a standard unit of measurement.

Authors must give their complete professional identifications and affiliations, including all academic titles and positions.

Letters to the editor should be brief (500 words or less) and offer objective, constructive and educational criticism of published material. The editor reserves the right to publish.

Figures: Two original copies (not negatives) of each figure are requested. Each figure should have a label on the back indicating its number, author's name and top of the figure. Do not write on the back of the figures and do not mount them on cardboard. **If sending colour pictures advise if they must be printed in colour or black and white (colour costs ten times more).**

Legends should be typed on a separate page with Arabic numerals corresponding to the illustrations.

Tables should be titled, typed in double space on separate pages and numbered in Arabic numerals in the order of their first citation in the text. Do not use internal rules. Only standard, universally understood abbreviations should be used.

References should be numbered consecutively in the order in which they are first mentioned in the text. Identify references in the text, tables, and legends by Arabic numerals in parentheses.

Use the style of the examples below, which are based with slight modifications on the format used by the U.S. National Library of Medicine in *Index Medicus*. The titles of journals should be abbreviated according to the style used in *Index Medicus*.

References must be verified by the Author(s) against the original documents.

Examples of correct forms of references are given below:

Articles in Journals: Authors' surname and initials (if more than six names, give six followed by "et al."), Title, Abbreviated Journal Title, Year of Publication, Volume, Issue and first page.

Books: Authors' surname and initials, title of the book and title of chapter, in: Title, Editor(s), Place, Publisher, Year, Page.

Acknowledgments will be limited to appropriate professionals who were contributors to the paper.

PROOFS revised by the editorial staff will be sent to the corresponding author and should be checked and returned within ten days. The corresponding author is responsible for detecting typesetting errors. After this deadline **the proofs will be considered approved.** Only essential corrections should be made; extensive changes will be charged to the authors.

BUSINESS MATTERS

The Journal has no commercial advertisements.

Authors will be expected to contribute to the printing expenses, tables, figures and postage. For every published article a copy of the Journal will be provided free of charge. **Only payments in US dollars will be accepted.** No bank transfers.

Reprints should be requested with the form enclosed with the acceptance letter. No free reprints will be supplied.

DISTINGUISHED EXPERT SERIES

- Prophylactic HPV vaccines** 165
 A. Szarewski - *London, UK*
 HPV vaccines have the potential to prevent at least 70% of cervical cancers and should also impact on the incidence of other genital cancers.

ORIGINAL ARTICLES

- Analysis of outcome of Stage I-III endometrial cancer treated with systematic operation omitting paraaortic lymphadenectomy** 170
 S. Kyo, M. Hashimoto, Y. Maida, Y. Mizumoto, M. Nakamura, M. Takakura, M. Inoue - *Ishikawa, JAPAN*
 Omission of paraaortic lymphadenectomy may be acceptable for endometrial cancer patients without gross metastasis at this site.
- Weekly paclitaxel in the treatment of recurrent ovarian carcinoma** 174
 L. Byrd, F.C. Thistlethwaite, A. Clamp, C. Ton, J. Hasan, G.C. Jayson - *Manchester, UK*
 Demonstration of efficacy and tolerability of weekly paclitaxel in the treatment of recurrent ovarian and peritoneal carcinoma in a drug-resistant setting following multiple lines of prior therapy.
- Expression and significance of the protein and mRNA of metastasis suppressor gene Me491/cd63 and integrin $\alpha 5$ in ovarian cancer tissues** 179
 X. Zhijun, Z. Shulan, Z. Zhuo - *Liaoning, CHINA*
 The expression and significance of the proteins and mRNA of metastasis suppressor gene Me491/cd63 and integrin $\alpha 5$ in ovarian cancer tissues were investigated.
- Expression of gelatinase (MMP-2 and MMP-9) and cyclooxygenase-2 (COX-2) in endometrial carcinoma** 184
 N. Karahan, M. Güney, S. Baspınar, B. Oral, N. Kapucuoglu, T. Mungan - *Isparta, TURKEY*
 COX-2, MMP-2 and MMP-9 are expressed in a high percentage of primary endometrial carcinomas and the expressions may be associated closely with parameters of tumor aggressiveness.
- Cervical intraepithelial neoplasia: risk factors for persistence and recurrence in adolescents** 189
 G. Vetrano, G. Lombardi, G. Di Leone, A. Parisi, P. Scardamaglia, G. Pate, M. Verrico, R. Corosu - *Rome, ITALY*
 HPV is the most common sexually transmitted disease in adolescents. Risk factors, progression of HPV lesions and CIN were evaluated.
- Prediction of myometrial invasion in patients with endometrial carcinoma: Comparison of magnetic resonance imaging, transvaginal ultrasonography, and gross visual inspection** 193
 T. Yahata, Y. Aoki, K. Tanaka - *Niigata, JAPAN*
 MRI, TVUS, and GVI are reliable for evaluation of deep myometrial invasion but not for superficial invasion in endometrial cancer.
- Treatment results and prognostic factors for cervical cancer patients treated by radiochemotherapy with weekly cisplatin** 196
 Z. Ozsaran, S. Kamer, D. Yalman, O. Akagunduz, A. Aras - *Izmir, TURKEY*
 A clinical trial with radiochemotherapy in locally advanced cervical cancer is presented.
- Ultrasound and MRI before and after radical hysterectomy: does the operation affect the pelvic floor muscles?** 201
 S.M. Axelsen, L. Gammelgaard, L.K. Petersen - *Aarhus, DENMARK*
 Mobility of the bladder neck and size of the pelvic floor muscles regenerated almost to the preoperative level one year after radical hysterectomy.
- The role of HPV DNA in the evaluation and follow-up of asymptomatic male sexual partners of females with CIN3** 207
 A. Bar-Am, J. Niv - *Tel-Aviv, ISRAEL*
 Asymptomatic male sexual partners of females with CIN3 should undergo combined androscopy and reflex HPV and cytology testing.

Postoperative radiotherapy in Stage IB squamous cell cervical cancer	211
V. Kukura, S. Ciglar, L. Markulin-Grgić, F. Šantek, J. Valetić - G. Zovko, P. Podolski - <i>Zagreb, CROATIA</i> Postoperative whole pelvic radiation for high-risk patients with FIGO Stage IB cervical cancer was evaluated.	
Investigation of Keyes skin biopsy instrument for cervical biopsy procedures versus Kevorkian biopsy forceps	214
S. Ayas, I. Aköz, A. Gürbüz, E. Eskicirak, H. Çetiner, A. Karateke - <i>Istanbul, TURKEY</i> The utility and efficacy of the Keyes skin biopsy instrument for cervical biopsy procedures were investigated.	
Clinical cytohistologic correlations of lesions of the female genital tract: Our experience in Panama	217
J.L. Garrido Martínez, M.M. Díaz, A. Villarreal - <i>Panama City, REPUBLIC OF PANAMA</i> Correlations between clinical cytological and pathological lesions of the female genital tract were studied in different areas of the Panama Republic.	
CASE REPORTS	
Management of vulvar melanoma and review of the literature	220
F.S. Suwandinata, R.M. Bohle, C.A. Omwandho, H.R. Tinneberg, S.E. Gruessner - <i>Giessen, GERMANY</i> Vulvar melanoma represents a rare group of malignancies, but it is the second most common vulvar malignancy. The whole concept of therapy should be tailored to the needs of individual patients. No improvement in the overall recovery or disease survival rate was shown in these primary retrospective series.	
Peritoneal metastasis in primary cervical cancer: a case report	225
M.J. Tseng, K.C. Ho, G. Lin, T.C. Yen, C.S. Tsai, C.H. Lai - <i>Taoyuan, TAIWAN</i> A cervical cancer patient whose peritoneal metastasis identified by FDG-PET during chemoradiation was successfully treated with curative-intent therapy.	
Vulvar primitive melanoma and sentinel lymph node: case report	229
E. Migliano, C. Monarca, L. Mariani, M. Tedesco, S. Bucher - <i>Rome, ITALY</i> A case of vulvar melanoma and the surgical treatment by vulvectomy, sentinel node dissection, and the following reconstructive procedure are reported.	
Bilateral Brenner tumor with endometrial adenocarcinoma in a postmenopausal woman	233
U. Indraccolo, N. Cingolani, S.R. Indraccolo - <i>Macerata, ITALY</i> A case of endometrial adenocarcinoma in a high-risk patient affected by Brenner tumor is reported.	
5-Fluorouracil cardiotoxicity complicating treatment of Stage IIB cervical cancer - case report	235
J.P. Geisler, K.J. Manahan, J.K. Rippy - <i>Indianapolis, IN (USA)</i> Reversible 5-fluorouracil cardiomyopathy is a rare complication of radiation sensitizing therapy in the treatment of cervix cancer.	
Androgenic juvenile granulosa cell tumor of the ovary with cystic presentation: a case report	236
R.S. Nomelini, A.M.R. Micheletti, S.J. Adad, E.F.C. Murta - <i>Uberaba-MG, BRAZIL</i> A case of juvenile granulosa cell tumor with unilocular cystic, androgenic manifestations and luteinized stromal cells is presented.	
Endometrial carcinoma presenting as hematometra: Clinicopathological study of a rare case and literature review	239
N. Salakos, K. Bakalianou, E. Deligeoroglou, A. Kondi-Pafiti, K. Papadias, G. Creatsas - <i>Athens, GREECE</i> A rare case of endometrial adenocarcinoma presenting as hematometra in a postmenopausal woman is presented.	
Ovarian clear cell adenocarcinoma producing alpha-fetoprotein: case report	241
A. Cetin, Z. Bahat, P. Cikesiz, N. Demirbağ, E. Yavuz - <i>Istanbul, TURKEY</i> A case of ovarian clear cell carcinoma with a serous component producing AFP and also elevated CA-125 levels is presented.	